Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019" report has been added to ResearchAndMarkets.com's offering.

This report provides an overview of Lung Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Lung Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

Scope

• Extensive coverage of the Lung Cancer Diagnostic Tests under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Lung Cancer Diagnostic Tests and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to buy

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of Lung Cancer Diagnostic Tests under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date
  

Key Topics Covered:

1 Introduction

1.1 Lung Cancer Diagnostic Tests Overview

2 Products under Development

2.1 Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development

2.2 Lung Cancer Diagnostic Tests - Pipeline Products by Territory

2.3 Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path

2.4 Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date

2.5 Lung Cancer Diagnostic Tests - Ongoing Clinical Trials

3 Lung Cancer Diagnostic Tests - Pipeline Products under Development by Companies

3.1 Lung Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development

3.2 Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development

4 Lung Cancer Diagnostic Tests Companies and Product Overview

5 Lung Cancer Diagnostic Tests - Recent Developments

6 Appendix

Companies Mentioned

• A&G Pharmaceutical Inc
• Abbott Diagnostics
• Abcodia Ltd
• Aberystwyth University
• Abnova Corp
• Acobiom
• Advanced Marker Discovery SL
• AIT Austrian Institute of Technology GmbH
• Almac Diagnostic Services Ltd
• ANGLE plc
• Anixa Diagnostics Corporation
• Armune BioScience Inc
• Aurelium BioPharma Inc.
• Avant Diagnostics Inc
• BARD1 Life Sciences Ltd
• BioAffinity Technologies, Inc.
• Biocept Inc
• Biodesix Inc
• Biological Dynamics Inc
• BioMark Diagnostics Inc
• BioMarker Strategies LLC
• BioNTech SE
• BioSystems International
• Boston Children's Hospital
• Cancer Genetics Inc
• Cancer Research Technology Ltd
• Cangen Biotechnologies Inc (Inactive)
• CDI Laboratories Inc
• Celcuity Inc
• Cellanyx Diagnostics, Inc.
• Cellmid Ltd
• CeMines, Inc. (Inactive)
• Cepheid
• Ceres Nanosciences Inc
• Cernostics Inc
• ChemImage Corp
• Clarient Inc
• Courtagen Life Sciences Inc
• DiagnoCure Inc. (Inactive)
• EDP Biotech Corporation
• Emory University
• Enterome Bioscience SA
• Epic Sciences Inc
• Epigenomics AG
• Eventus Diagnostics Inc (Inactive)
• Exact Sciences Corp
• Exiqon AS
• Exosomics Siena SpA
• Fahy Gurteen UK Ltd
• And Many Many More Companies!
  

For more information about this report visit https://www.researchandmarkets.com/r/nzdn5j